By Dan Weil Wood’s flagship Ark Innovation ETF has sunk 53% so far this year, as her technology companies have hit the skids. Celebrity investor Cathie Wood, chief executive of Ark Investment Management, sold shares of a major pharmaceutical company and traded in some of her usual names June 8. All the valuations below are as of June 8’s close. The pharma company is Pfizer (PFE) – Get Pfizer Inc. Report, which doesn’t match the young, “disruptive” technology companies that make up the bulk of Wood’s portfolio. In any case, Ark Genomic Revolution ETF (ARKG) – Get ARK Genomic Revolution ETF Repo…